SGLT-2-Inhibitoren – Glukosurika: Ein neues wertvolles Therapieprinzip oder ein Irrweg?

G. Schernthaner; D. Müller-Wieland; B. Gallwitz

doi:10.1055/s-0031-1283929

Diabetologie und Stoffwechsel, Table of Contents

Diabetologie und Stoffwechsel 2012; 7(1): 27-29
DOI: 10.1055/s-0031-1283929

Editorial

SGLT-2-Inhibitoren – Glukosurika: Ein neues wertvolles Therapieprinzip oder ein Irrweg?

SGLT-2 Inhibitors – Glucosuric Compounds: A Valuable Novel Development or Not?

G. Schernthaner

¹1. Medizinische Abteilung Diabetologie, Endokrinologie und Onkologie, Krankenanstalt Rudolfstiftung, Wien, Österreich

,

D. Müller-Wieland

²Allg. Inneren Medizin, Gastroenterologie, Endokrinologie, Diabetologie & Stoffwechsel Asklepios Klinik St. Georg, Hamburg, Deutschland

,

B. Gallwitz

³Medizinische Klinik IV, Universitätsklinikum Tübingen, Tübingen, Deutschland

› Author Affiliations

Abstract

Full Text

References

Literatur
1 Goodson JD, Singer DE, Hurxthal K et al. The limited clinical value of home urine testing by diabetic patients. J Gen Intern Med 1986; 1: 243-247
2 Gerich JE. Role of the kidney in normal glucose homeostasis and in the hyperglycemia of diabetes mellitus: therapeutic implications. Diabet Med 2010; 27: 136-142
3 Souza-Menezes J, Morales MM, Tukaye DN et al. Absence of ClC5 in knockout mice leads to glycosuria, impaired renal glucose handling and low proximal tubule GLUT2 protein expression. Cell Physiol Biochem 2007; 20: 455-464
4 Jurczak MJ, Lee HY, Birkenfeld AL et al. SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function. Diabetes 2011; 60: 890-898
5 Santer R, Calado J. Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target. Clin J Am Soc Nephrol 2010; 5: 133-141
6 Musso G, Gambino R, Cassader M et al. A novel approach to control hyperglycemia in type 2 diabetes: Sodium glucose co-transport (SGLT) inhibitors. Systematic review and meta-analysis of randomized trials. Ann Med 2011; [Epub ahead of print]
7 Grempler R, Thomas L, Eckhardt M et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab 2012; 14: 83-90
8 http://www.clinicaltrials.gov
9 List JF, Woo V, Morales E et al. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 2009; 32: 650-657
10 http://www.FDA.gov (Background Document. Dapagliflozin. BMS-512148, NDA 202293, Jun / July 2011)
11 Strojek K, Yoon KH, Hruba V et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab 2011; 13: 928-938
12 Bailey CJ, Gross JL, Pieters A et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 2010; 375: 2223-2233
13 Nauck MA, Del Prato S, Meier JJ et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care 2011; 34: 2015-2022
14 Kasichayanula S, Liu X, Shyu WC et al. Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects. Diabetes Obes Metab 2011; 13: 47-54
15 Wilding JP, Norwood P, T'joen C et al. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care 2009; 32: 1656-1662
16 Ferrannini E, Ramos SJ, Salsali A et al. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 2010; 33: 2217-2224
17 Komoroski B, Vachharajani N, Feng Y et al. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther 2009; 85: 513-519 Erratum in: Clin Pharmacol Ther 2009; 85: 558
18 Zhang L, Feng Y, List J et al. Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight. Diabetes Obes Metab 2010; 12: 510-516
19 Sha S, Devineni D, Ghosh A et al. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab 2011; 13: 669-672
20 UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352 (9131) 854-865
21 Kahn SE, Haffner SM, Heise MA. ADOPT Study Group et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-2443 Erratum in: N Engl J Med 2007; 356: 1387–1388
22 http://www.bms.com/news/press_releases/pages/default.aspx
23 DeFronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009; 58: 773-795
24 Taharani AA, Bailey CJ, Del PratoS et al. Management of type 2 diabetes: new and future developments in treatment. Lancet 2011; 378: 182-197